Zhang et al. demonstrated that molecular genetic methods significantly improve FLT3 and NPM1 mutation detection in AML, especially in cases with a normal karyotype where cytogenetics yield no significant findings [25]. This evidence concerns the gene NPM1 and acute myeloid leukemia.